Low-Density Lipoprotein-Mimicking Nanoparticles for Tumor-Targeted Theranostic Applications

被引:25
|
作者
Lee, Jeong Yu [1 ]
Kim, Jin-Ho [1 ,2 ,3 ]
Bae, Ki Hyun [4 ]
Oh, Mi Hwa [4 ]
Kim, Youngwook [2 ]
Kim, Jee Seon
Park, Tae Gwan [4 ]
Park, Keunchil [2 ,5 ]
Lee, Jung Hee [3 ,6 ]
Nam, Yoon Sung [1 ,4 ,7 ]
机构
[1] Korea Adv Inst Sci & Technol, Dept Mat Sci & Engn, Taejon 305701, South Korea
[2] Samsung Biomed Res Inst, Med Nanoelement Dev Ctr, Seoul 135710, South Korea
[3] Sungkyunkwan Univ, Dept Hlth Sci & Technol, Samsung Adv Inst Hlth Sci & Technol, Seoul 135710, South Korea
[4] Korea Adv Inst Sci & Technol, Dept Biol Sci, Taejon 305701, South Korea
[5] Sungkyunkwan Univ, Div Hematol & Oncol, Samsung Med Ctr, Dept Med,Sch Med, Seoul 135710, South Korea
[6] Sungkyunkwan Univ, Samsung Med Ctr, Dept Radiol, Sch Med, Seoul 135710, South Korea
[7] Korea Adv Inst Sci & Technol, KAIST Inst NanoCentury KINC, KAIST Inst BioCentury KIB, Taejon 305701, South Korea
基金
新加坡国家研究基金会;
关键词
low-density lipoproteins; nanoparticles; anti-cancer agents; self-assembly; imaging; MANGANESE OXIDE NANOPARTICLES; MAGNETIC-RESONANCE; DRUG-DELIVERY; IRON-OXIDE; IN-VIVO; SIRNA DELIVERY; CANCER-CELLS; PACLITAXEL; RECEPTOR; FORMULATION;
D O I
10.1002/smll.201303277
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
This study introduces multifunctional lipid nanoparticles (LNPs), mimicking the structure and compositions of low-density lipoproteins, for the tumor-targeted co-delivery of anti-cancer drugs and superparamagnetic nanocrystals. Paclitaxel (4.7 wt%) and iron oxide nanocrystals (6.8 wt%, 11 nm in diameter) are co-encapsulated within folate-functionalized LNPs, which contain a cluster of nanocrystals with an overall diameter of about 170 nm and a zeta potential of about -40 mV. The folate-functionalized LNPs enable the targeted detection of MCF-7, human breast adenocarcinoma expressing folate receptors, in T-2-weighted magnetic resonance images as well as the efficient intracellular delivery of paclitaxel. Paclitaxel-free LNPs show no significant cytotoxicity up to 0.2 mg mL(-1), indicating the excellent biocompatibility of the LNPs for intracellular drug delivery applications. The targeted anti-tumor activities of the LNPs in a mouse tumor model suggest that the low-density lipoprotein-mimetic LNPs can be an effective theranostic platform with excellent biocompatibility for the tumor-targeted co-delivery of various anti-cancer agents.
引用
收藏
页码:222 / 231
页数:10
相关论文
共 50 条
  • [41] THE LOW-DENSITY LIPOPROTEIN RECEPTOR
    SCHNEIDER, WJ
    [J]. BIOCHIMICA ET BIOPHYSICA ACTA, 1989, 988 (02) : 303 - 317
  • [42] From one to all: self-assembled theranostic nanoparticles for tumor-targeted imaging and programmed photoactive therapy
    Li, Xianlei
    Wang, Xuan
    Zhao, Caiyan
    Shao, Leihou
    Lu, Jianqing
    Tong, Yujia
    Chen, Long
    Cui, Xinyue
    Sun, Huiling
    Liu, Junxing
    Li, Mingjun
    Deng, Xiongwei
    Wu, Yan
    [J]. JOURNAL OF NANOBIOTECHNOLOGY, 2019, 17 (1)
  • [43] From one to all: self-assembled theranostic nanoparticles for tumor-targeted imaging and programmed photoactive therapy
    Xianlei Li
    Xuan Wang
    Caiyan Zhao
    Leihou Shao
    Jianqing Lu
    Yujia Tong
    Long Chen
    Xinyue Cui
    Huiling Sun
    Junxing Liu
    Mingjun Li
    Xiongwei Deng
    Yan Wu
    [J]. Journal of Nanobiotechnology, 17
  • [44] Fenofibrate lowers small low-density lipoprotein with no change in total low-density lipoprotein cholesterol
    Superko, HR
    Madan, S
    Tonnemacher, D
    Chronos, N
    Garrett, B
    Sheehan, D
    Raul, E
    Frohwein, S
    McGrath, K
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2003, 41 (06) : 316A - 316A
  • [45] Non-oxidative modification of native low-density lipoprotein by oxidized low-density lipoprotein
    Yang, M
    Leake, DS
    RiceEvans, CA
    [J]. BIOCHEMICAL JOURNAL, 1996, 316 : 377 - 380
  • [46] Increased circulating oxidised low-density lipoprotein and antibodies to oxidised low-density lipoprotein in preeclampsia
    Arifin, Rosemawati
    Kyi, Win Mar
    Yaakob, Che Anuar Che
    Yaacob, Najib Majdi
    [J]. JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 2017, 37 (05) : 580 - 584
  • [47] ACTIVATION OF LOW-DENSITY LIPOPROTEIN RECEPTOR SYNTHESIS BY TREATMENT WITH PARTIALLY DELIPIDATED LOW-DENSITY LIPOPROTEIN
    LEUNG, AM
    CHEUNG, WK
    HO, WKK
    [J]. INTERNATIONAL JOURNAL OF BIOCHEMISTRY, 1983, 15 (07): : 929 - 934
  • [48] Inclisiran, Low-Density Lipoprotein Cholesterol and Lipoprotein (a)
    Katsiki, Niki
    Vrablik, Michal
    Banach, Maciej
    Gouni-Berthold, Ioanna
    [J]. PHARMACEUTICALS, 2023, 16 (04)
  • [49] IS VERY LOW-DENSITY LIPOPROTEIN NECESSARY FOR FORMATION OF NORMAL SIZE LOW-DENSITY LIPOPROTEIN POPULATIONS
    DECKELBAUM, R
    OSCHRY, Y
    EISENBERG, S
    CARROLL, R
    RUDEL, L
    [J]. ARTERIOSCLEROSIS, 1982, 2 (05): : A437 - A437
  • [50] Baseline levels of low-density lipoprotein cholesterol and lipoprotein (a) and the AvaII polymorphism of the low-density lipoprotein receptor gene influence the response of low-density lipoprotein cholesterol to pravastatin treatment
    Lahoz, C
    Peña, R
    Mostaza, JM
    Laguna, F
    García-Iglesias, MF
    Taboada, M
    Pintó, X
    [J]. METABOLISM-CLINICAL AND EXPERIMENTAL, 2005, 54 (06): : 741 - 747